Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Thomas W. T. Leung"'
Autor:
Nathalie Wong, Kathy Y-Y. Chan, Pascale F. Macgregor, Paul B-S. Lai, Jeremy A. Squire, Ben Beheshti, Monique Albert, Thomas W-T. Leung
Publikováno v:
Clinical Cancer Research. 11:1319-1326
Purpose: Treatment with IFN-α therapy has been shown to exhibit antitumor effects on patients with hepatocellular carcinoma (HCC). However, individual responses remained unpredictable because of the frequent presence of intrinsic or acquired IFN-α
Autor:
John H. S. Chow, Wing Y. Chan, Tony S. K. Mok, Anthony P. C. Yim, Kwok Chi Lam, Thomas W. T. Leung, Anthony T.C. Chan, Peter M.L. Teo, Philip J. Johnson, Wing H. Kwan
Publikováno v:
Cancer. 83:925-929
BACKGROUND Lymphoepithelioma-like carcinoma (LELC) of the lung occurs at a higher frequency in Asian compared with Western patients. Its association with Epstein-Barr virus varies among different ethnic groups. METHODS Nine patients with primary LELC
Autor:
Stephen L, Chan, Frankie K F, Mo, Philip J, Johnson, Giok S, Liem, Tung C, Chan, Ming C, Poon, Brigette B Y, Ma, Thomas W T, Leung, Paul B S, Lai, Anthony T C, Chan, Tony S K, Mok, Winnie, Yeo
Publikováno v:
Journal of gastroenterology and hepatology. 26(2)
Hepatitis B viral (HBV) infection is the predominant etiology of hepatocellular carcinoma (HCC) in Asia. Our group previously reported a staging system known as the Chinese University Prognostic Index (CUPI) for HCC populations of which HBV infection
Autor:
Nathalie, Wong, Kathy Y-Y, Chan, Pascale F, Macgregor, Paul B-S, Lai, Jeremy A, Squire, Ben, Beheshti, Monique, Albert, Thomas W-T, Leung
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 11(3)
Treatment with IFN-alpha therapy has been shown to exhibit antitumor effects on patients with hepatocellular carcinoma (HCC). However, individual responses remained unpredictable because of the frequent presence of intrinsic or acquired IFN-alpha res
Autor:
Ying, Hu, Elizabeth, Pang, Paul B-S, Lai, Jeremy A, Squire, Pascale F, MacGregor, Ben, Beheshti, Monique, Albert, Thomas W-T, Leung, Nathalie, Wong
Publikováno v:
International journal of oncology. 25(5)
Despite a prolongation of patient survival, the overall response of doxorubicin (DX) treatment on patients with hepatocellular carcinoma (HCC) remains modest. This is largely attributed to the development of tumor drug resistance either at the onset
Autor:
Masayo, Kotaka, George G, Chen, Paul B S, Lai, Wan Y, Lau, Paul K S, Chan, Thomas W T, Leung, Authur K C, Li
Publikováno v:
Oncology research. 13(3)
Hepatitis C virus (HCV) infection is associated with pathogenesis of hepatocellular carcinoma (HCC). We carried out suppression subtractive hybridization to identify variable expression of genes linked to HCC with HCV infection. RNA from both tumorou
Autor:
Terence C W, Poon, Tony S K, Mok, Anthony T C, Chan, Charles M L, Chan, Veronica, Leong, Steven H T, Tsui, Thomas W T, Leung, Herman T M, Wong, Stephen K W, Ho, Philip J, Johnson
Publikováno v:
Clinical chemistry. 48(7)
At concentrations500 microg/L, serum alpha-fetoprotein (AFP) has low specificity in the diagnosis of hepatocellular carcinoma (HCC), but monosialylated AFP (msAFP) is more specific for HCC. We describe two strategies for quantitative analysis of msAF
Autor:
Simon C.H. Yu, Paul B. S. Lai, Thomas W. T. Leung, Wan Yee Lau, Amanda M. Y. Tang, Joseph Lau, Philip J. Johnson, Benny Zee, Ka-Lau Leung
Publikováno v:
Cancer. 94(6)
BACKGROUND The current TNM staging system for patients with hepatocellular carcinoma (HCC) does not include liver function parameters and does not provide a precise prognosis for patients in different risk groups. The objectives of this study were to
Autor:
Benny Zee, Simon C.H. Yu, Paul B. S. Lai, Philip J. Johnson, Wan Yee Lau, Thomas W. T. Leung, Amanda M. Y. Tang
Publikováno v:
Cancer. 94(2)
BACKGROUND The objective of the current study was to identify patient and disease related factors that influence response and survival for patients with unresectable hepatocellular carcinoma (HCC) who received a systemic combination chemotherapy cons